跳至主要内容
临床试验/CTRI/2018/07/014823
CTRI/2018/07/014823尚未招募未知

An exploratory pilot clinical validation study to correlate clinical outcome between physician decided therapy and its CANscriptTM response prediction in metastatic Castration Resistant Prostate Cancer (mCRPC) patients.

Dr SK Raghunath0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Patient diagnosed as mCRPC with rising PSA
  • levels and for whom physician has already
  • decided to initiate abiraterone alone or in
  • combination with other drug
  • 2. Men >= 18 years of age
  • 3. ECOG performance status ï?£ 2
  • 4. Patientâ??s tumour (primary or metastatic
  • sites) must be amenable to a fresh tumour
  • biopsy sampling using surgical/excision
  • biopsy or core biopsy, so that CANscript can
  • be performed. Decision to perform biopsy
  • will be outside the study protocol and as
  • per routine clinical decision by treating
  • 5. Patient willing to provide written informed
  • consent for study participation

排除标准

  • 1. Patient has any medical condition, which in the
  • opinion of the investigator places the patient
  • at an unacceptably high risk for study related

研究者

发起方
Dr SK Raghunath

相似试验